Shennon Biotechnologies

ShennonBio develops precision immunotherapies for solid tumors. Its TCELERATOR platform profiles more than 10 million single-cell interactions at once, combined with computational binder design, translational immunology and predictive safety assessment. The company develops both antibody-based and TCR-based T-cell engagers for surface and intracellular cancer targets.

Its initial oncology pipeline includes programs in small cell lung cancer, ovarian cancer and hepatocellular carcinoma. Its proprietary human tumor datasets are built through a network of academic and clinical collaborators across 15 institutions. The company raised $13M in seed financing in 2023 and $12M in September 2026, the latter alongside the appointment of Cyril Konto, MD, as chief executive officer.

The first technology dates back to 2015, when the founding team worked at Harvard University. The company is headquartered in San Francisco, with laboratory and office space near UCSF Mission Bay, including wet labs and an in-house clean room for microchip fabrication. Open roles include T-cell engager development scientists, a Chief Scientific Officer / VP of R&D, and a CMC lead for multispecific antibodies.

Product: TCELERATOR single-cell functional screening platform and a pipeline of antibody-based and TCR-based T-cell engagers for solid tumors.